##gff-version 3
##sequence-region Q14686 1 2063
Q14686	UniProtKB	Chain	1	2063	.	.	.	ID=PRO_0000094413;Note=Nuclear receptor coactivator 6	
Q14686	UniProtKB	Region	1	1310	.	.	.	Note=NCOA1-binding region	
Q14686	UniProtKB	Region	1	1057	.	.	.	Note=CREBBP-binding region	
Q14686	UniProtKB	Region	1	928	.	.	.	Note=TBP/GTF2A-binding region	
Q14686	UniProtKB	Region	773	927	.	.	.	Note=NCOA6IP-binding region	
Q14686	UniProtKB	Region	1641	2063	.	.	.	Note=EP300/CRSP3-binding region	
Q14686	UniProtKB	Motif	887	891	.	.	.	Note=LXXLL motif 1	
Q14686	UniProtKB	Motif	1491	1495	.	.	.	Note=LXXLL motif 2	
Q14686	UniProtKB	Compositional bias	227	1041	.	.	.	Note=Gln-rich	
Q14686	UniProtKB	Compositional bias	372	377	.	.	.	Note=Poly-Pro	
Q14686	UniProtKB	Compositional bias	913	918	.	.	.	Note=Poly-Lys	
Q14686	UniProtKB	Modified residue	95	95	.	.	.	Note=Asymmetric dimethylarginine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:24129315;Dbxref=PMID:24129315	
Q14686	UniProtKB	Modified residue	884	884	.	.	.	Note=Phosphoserine%3B by MAPK%3B in vitro;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11773444;Dbxref=PMID:11773444	
Q14686	UniProtKB	Modified residue	1047	1047	.	.	.	Note=Asymmetric dimethylarginine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9JL19	
Q14686	UniProtKB	Modified residue	1058	1058	.	.	.	Note=Asymmetric dimethylarginine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9JL19	
Q14686	UniProtKB	Modified residue	1096	1096	.	.	.	Note=Asymmetric dimethylarginine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9JL19	
Q14686	UniProtKB	Modified residue	1819	1819	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9JL19	
Q14686	UniProtKB	Modified residue	1822	1822	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q9JL19	
Q14686	UniProtKB	Modified residue	2018	2018	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
Q14686	UniProtKB	Natural variant	512	512	.	.	.	ID=VAR_027874;Note=P->L;Dbxref=dbSNP:rs6060031	
Q14686	UniProtKB	Natural variant	955	955	.	.	.	ID=VAR_027875;Note=N->S;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10567404,ECO:0000269|PubMed:10681503,ECO:0000269|PubMed:10823961,ECO:0000269|PubMed:10866662,ECO:0000269|PubMed:8724849;Dbxref=dbSNP:rs17092079,PMID:10567404,PMID:10681503,PMID:10823961,PMID:10866662,PMID:8724849	
Q14686	UniProtKB	Natural variant	1060	1060	.	.	.	ID=VAR_036551;Note=In a breast cancer sample%3B somatic mutation. P->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16959974;Dbxref=PMID:16959974	
Q14686	UniProtKB	Natural variant	1191	1191	.	.	.	ID=VAR_036552;Note=In a breast cancer sample%3B somatic mutation. S->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16959974;Dbxref=PMID:16959974	
Q14686	UniProtKB	Natural variant	1995	1995	.	.	.	ID=VAR_027876;Note=I->V;Dbxref=dbSNP:rs6060022	
Q14686	UniProtKB	Mutagenesis	883	894	.	.	.	Note=Reduced binding to THRB%2C RXRA%2C ESR2 and ESR1. TSPLLVNLLQSD->ENPLLVNLLQFI;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11773444;Dbxref=PMID:11773444	
Q14686	UniProtKB	Mutagenesis	883	894	.	.	.	Note=Reduced binding to THRB%2C RXRA%2C ESR2 and ESR1. TSPLLVNLLQSD->NLPLLVNLLQHT;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11773444;Dbxref=PMID:11773444	
Q14686	UniProtKB	Mutagenesis	883	894	.	.	.	Note=Reduced binding to THRB%2C RXRA%2C ESR2 and ESR1. TSPLLVNLLQSD->VNPLLVNLLQFI;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11773444;Dbxref=PMID:11773444	
Q14686	UniProtKB	Mutagenesis	883	884	.	.	.	Note=Strong increase in binding to THRB%2C RXRA and ESR2%2C but dramatic decrease in binding to ESR1. TS->SY	
Q14686	UniProtKB	Mutagenesis	884	894	.	.	.	Note=Reduced binding to THRB%2C RXRA%2C ESR2 and ESR1. SPLLVNLLQSD->NPLLVNLLQLL	
